Galmed Pharmaceuticals (GLMD) Stock: Buy, Sell, or Hold?
GLMD - Galmed Pharmaceuticals Ltd.
$4.63
0.80 (21.05%)
â˛
5d:
+17.96%
30d:
+680.64%
90d:
+787.31%
WAIT
LOW Confidence
Analysis Updated: Sep 9, 2026 12:00 AM ET
Earnings: Aug 27, 2026
0d
Get Alerted When GLMD Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: GLMD is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: GLMD is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: GLMD is currently trading at $4.63, which is considered fair based on recent price action.
Technical Outlook: Technically, GLMD is in a strong uptrend. The price is approaching resistance at $4.63. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 21.0% recently.
Market Sentiment: GLMD scores 16/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $12.00 (+159.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, GLMD is in a strong uptrend. The price is approaching resistance at $4.63. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 21.0% recently.
Market Sentiment: GLMD scores 16/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $12.00 (+159.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Company Quality Score
37/100
(SELL)
Volume Confirmation
UNKNOWN
Confidence Score
50.0%
All Signals
- NEUTRAL: Price in fair range
- BEARISH: Weak technical setup (16/100)
- BULLISH: Strong upward momentum (+21.0%)
- BULLISH: Trading 159.2% below Wall St target ($12.00)
- WARNING: Composite score 36/100 in the bottom quintile â this cohort historically lags the market
Support & Resistance Levels
Support Level
$3.74
Resistance Level
$4.63
Current Trend
Strong Uptrend
Technical data as of
Sep 9, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-0.64
Wall Street Target
$12.00
(+159.2%)
Share & Embed Analysis
Last updated: October 23, 2026 10:54 PM ET
Data refreshes hourly during market hours. Next update: 11:54 PM
Data refreshes hourly during market hours. Next update: 11:54 PM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is GLMD showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
JAZZ
Jazz Pharmaceuticals PLC |
STRONG BUY
22 analysts |
$295 | 64 BUY |
|
PRAX
Praxis Precision MedicinâĻ |
STRONG BUY
20 analysts |
$650 | 65 BUY |
|
REGN
Regeneron PharmaceuticalâĻ |
BUY
28 analysts |
$864 | 35 SELL |
|
ELVN
Enliven Therapeutics Inc. |
STRONG BUY
14 analysts |
$74 | 65 BUY |
|
ACAD
ACADIA Pharmaceuticals IâĻ |
STRONG BUY
20 analysts |
$31 | 61 BUY |
